Prospective Comprehensive Molecular Analysis of Endocrine Neoplasms

Launched by NATIONAL CANCER INSTITUTE (NCI) · Oct 30, 2009

Keywords

ClinConnect Summary

This clinical trial is focused on understanding endocrine neoplasms, which are tumors that can occur in glands like the thyroid, parathyroid, adrenal glands, and pancreas. These tumors are becoming more common, and it can be challenging to determine if they are benign (not cancerous) or malignant (cancerous). The researchers want to learn more about the molecular changes that happen as these tumors develop, so they are collecting tissue samples from patients who are undergoing surgery or biopsy for these tumors.

To be eligible for this study, patients must have a tumor in one of the mentioned glands and be scheduled for surgery at the National Institutes of Health Clinical Center. Participants will provide blood and urine samples before their surgery, and during the procedure, doctors will take samples of both the tumor and some healthy tissue nearby. After surgery, participants will receive standard medical care, and they will have follow-up appointments to monitor their recovery. This trial is important because it aims to enhance our understanding of these tumors, which could lead to better detection and treatment options for patients in the future.

Gender

ALL

Eligibility criteria

• * INCLUSION CRITERIA:
• • Participants who have an endocrine neoplasm based on radiographic and biochemical testing, or histologically/cytologically proven lesions of the thyroid, parathyroid, adrenal, extra-adrenal endocrine nests, paragangliomas, neuroblastomas, gastrointestinal
• • track and pancreas or participants with a described pre or potentially malignant condition that requires surgery or biopsy as a part of the standard of care treatment and/or follow up.
• • Participants referred to the Endocrine Consult Service on other protocols for surgical evaluation of endocrine disorders based on radiographic and biochemical testing, or histologically/cytologically proven lesions of the thyroid, parathyroid, adrenal, extra-adrenal endocrine nests, paragangliomas, neuroblastomas and pancreas.
• • Participants must have an ECOG performance score of 0-2.
• • Participants must have laboratory and physical examination parameters within acceptable limits by standard of practice guidelines prior to biopsy or surgery.
• • Participants must be planning to undergo surgery or biopsy as part of their treatment plan. Note: Participants will not be enrolled exclusively for the procurement of tissue samples.
• • Age \>= 4 years of age.
• EXCLUSION CRITERIA:
• • None.